13th Euro Abstracts associated with lower incidence of both symptomatic and severe hypoglycaemic events, resulting in an incremental benefi t of 0.12 QALYs and an incremental cost-effectiveness ratio (ICER) of c13,931 per QALY gained. Modest reductions in all macro-vascular and micro-vascular complications were seen in those receiving saxagliptin + MET compared with SU + MET. Sensitivity analysis showed that treatment-related weight changes, as a risk factor for complications, represent the most infl uential driver of costeffectiveness. CONCLUSIONS: Saxagliptin is associated with improved outcomes, a lower incidence of hypoglycaemic events, and weight neutrality, when compared with generic SU, at a cost that would likely be considered acceptable in the German setting.
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COST-EFFECTIVENESS ANALYSIS OF SAXAGLIPTIN IN THE TREATMENT OF DIABETES MELLITUS TYPE 2 IN SPAIN
Ramirez de Arellano A 1 , Brosa M 2 , Franch J 3 , Mauricio D 4 , Alvarez C 5 , Sanchez-Zamorano M 1 , De Rivas B 5 1 Bristol-Myers Squibb Iberia, Madrid, Spain; 2 Oblikue Consulting, Barcelona, Spain; 3 Red GEDAPS, Barcelona, Spain; 4 Hospital Universitario Arnau de Vilanova, Lerida, Spain, 5 AstraZeneca, Madrid, Spain OBJECTIVES: Saxagliptin is indicated as an add-on combination therapy for adult patients with diabetes mellitus type 2 (T2D) to improve glycaemic control in combination with metformin, a sulphonylurea (SU) or a thiazolidinedione (TZD) . The objective of this study was to evaluate the cost-effectiveness in Spain of saxagliptin when added to metformin in comparison with SU plus metformin or TZD plus metformin. METHODS: The analysis uses the Cardiff Long Term Model which simulates treatment pathways of pharmacological treatment of T2D from initiation of treatment until death. Effi cacy and safety data are based on an indirect comparison of saxagliptin and SU and TZD based on the similarity in safety and effi cacy between saxagliptin and sitagliptin demonstrated in a 18-week non-inferiority study (CV181,056). Available direct comparative trials between sitagliptin and TZDs and SUs are used to serve as data sources to assign effi cacy and safety parameters. Spanish costs are used as for macro and microvascular complications as well as adverse events such as severe hypoglycemia. Utility decrements for ischemic heart disease, myocardial infarction, congestive heart failure, stroke, blindness, end-stage renal disease, transplant, amputation and body mass index are also accounted in the model. Health outcomes are measured in terms of QALYs, assuming that the lifetime QALY is affected by complications, occurrence of hypoglycaemic episodes and weight changes. The perspective used is that of the Spanish Health System. RESULTS: Saxagliptin as add on to metformin is cost-effective compared with SU and TZD (ICER < c10,000). Extensive univariate sensitivity analysis shows that the most infl uential factor is the weight variation, which increases with treatment with SU and TZD whereas DPP-4 inhibitors have shown to be weight neutral. CONCLUSIONS:
The cost-effectiveness analysis shows that saxagliptin is cost-effective compared with both SU and TZD in combination with metformin for the treatment of T2DM in Spain.
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COST-EFFECTIVENESS OF NEW ANTIDIABETICS IN TYPE 2 DIABETES:
A REVIEW Baytar S, Malhan S Baskent University, Ankara, Turkey OBJECTIVES: Although having substantial costs, the new antidiabetics for Type 2 diabetes treatment present more alternatives for glycemic control of the disease. To evaluate their cost-effectiveness, the New Antidiabetics for Type 2 diabetes indexed on PubMed, EMBASE databases and American Diabetes Association abstracts were evaluated. METHODS: The cost-effectiveness of Type 2 diabetes based on the new antidiabetics was analyzed through literature review. Searches were carried out in PubMed, EMBASE and ADA abstracts to identify the articles published from 2008 to 2010, keying in the terms "cost-effectiveness" and "type 2 diabetes" with language fi ltering, "English." The language fi lter for "Turkish" was also used but no result was achieved. Upon this fi ltration, the abstracts were reviewed to determine whether they included antidiabetics. RESULTS: Ten full texts, seven abstracts and three peer reviews were identifi ed. In all studies, the cost-effectiveness of antidiabetics was assessed using the validated CORE Diabetes Model, except for two based on the Discrete Event Simulation Model. The outcomes from IMPROVE, PROactive, PRESENT, UKPDS and PREDICTIVE trials were used. In these studies, biphasic insulin aspart, exenatide, pioglitazone, insulin detemir, insulin glargine and sitagliptin were all studied under different settings and against various comparators. Biphasic insulin aspart versus human premix insulin was mostly found to be cost-effective in certain studies. Exenatide versus insulin glargine was established to be likely costeffective in two studies. Pioglitazone was found to be dominant compared to rosiglitazone. Insulin detemir was established to be cost-saving in comparison with OAD or NPH insulin, or insulin glargine. Sitagliptin was regarded as either cost-effective or cost-saving compared to rosiglitazone. CONCLUSIONS: Different results in terms of cost-effectiveness of various antidiabetics under certain settings and against varied comparators were achieved. In future, demonstrated gains in QALYs will be found to be essential for these antidiabetics to be regarded as cost-effective.
PDB47 THE COST-EFFECTIVENESS OF CONTINUOUS GLUCOSE MONITORING IN TYPE 1 DIABETES PATIENTS IN THE NETHERLANDS vanGenugten ML
Medtronic Trading NL BV, Heerlen, The Netherlands OBJECTIVES: Continuous glucose monitoring (CGM) has been found to improve glycemic control in type 1 diabetes in recent trials. The objective of this study is to assess the cost-effectiveness of CGM compared with self-monitoring of blood glucose (SMBG) in type 1 diabetes patients, from a societal perspective in the The Netherlands. METHODS: The analysis was performed using the CORE Diabetes model with inputs for the The Netherlands. Clinical effectiveness of CGM in terms of lowering HbA1c was taken from the GuardControl study. Costs of complications and complicationrelated days off work were based on data from Erasmus University Rotterdam. Annual treatment costs were estimated using cost information from the Healthcare Insurance Board. Costs and effects were discounted at 4% and 1.5%, respectively. a lifetime horizon (60 years) was adopted for the analysis. a range of sensitivity analyses were conducted. RESULTS: The total costs per patient over 60 years for the CGM arm were c10,069 (73,348) higher than costs for the SMBG arm. Complication costs were lower, and treatment costs were higher for the CGM compared to the SMBG arm. Compared to the SMBG arm, 0.463 (3.063) QALYs were gained in the CGM group. The cost per QALY gained was c21,731. Probabilistic sensitivity analyses showed that this result is robust. CONCLUSIONS: At a willingness to pay threshold of c40,000 per QALY, CGM appears to be a cost-effective treatment option compared to SMBG in patients with type 1 diabetes.
PDB48
COST-EFFECTIVENESS OF 2 DIABETES HEALTH CARE PROGRAMMES IN BELGIUM
Benoit K 1 , Borgermans L 2 , Annemans L 3 1 Ghent University, Ghent, Belgium; 2 Catholic University Leuven, Leuven, Belgium; 3 Ghent University-Brussels University, Ghent, Belgium OBJECTIVES: A multifaceted quality improvement programme for the care of diabetes was implemented in two different Flemish regions (Aalst and Leuven) and with slightly different modalities. The overall objective of the programmes was to improve adherence to evidence-based guidelines on diabetes in primary care physicians. The aim of this study was to assess the cost-effectiveness of the programs compared to regular care in both regions. METHODS: Short-term effects of the programmes were extrapolated to long-term hard endpoints, using the validated UKPDS Outcomes Model, supplemented by two self-developed Markov models to account for benefi ts on process parameters (screening for retinopathy and nephropathy). a simulation of the evolution of patients was made over a time horizon of 25 years with cycles of 1 year, from a public health care payer perspective. Cost data of the different disease states and extra direct medical costs due to intensifi ed patient management were collected from literature and from the National Institute for Health and Disability Insurance. For the self developed Markov models, utility data for all states were obtained from published studies and transition probabilities were obtained from local epidemiological studies and published trials. In the simulation, the intervention was assumed to be implemented three times over the predicted life expectancy. Deterministic sensitivity analyses were performed on the combined results of outcome and process parameters. RESULTS: At a cost of intervention of c185 (Aalst) and c284 (Leuven) per patient, the analyses show ICER'S for Aalst and Leuven of respectively c15,206.70/QALY and c10,397.96/QALY. Sensitivity analyses show few infl uence of changed input variables. CONCLUSIONS: When using a ratio of c30,000/QALY as threshold of willingness to pay for health gain, the diabetes health care programmes have an acceptable ICER in both regions.
PDB49 PHARMACOECONOMICS MODELING OF LONG TERM RESULTS OF TYPE 2 DIABETES MELLITUS TREATMENT IN PATIENTS USING MODERN INSULIN ANALOGUES IN CONTRAST TO ORAL ANTIDIABETIC DRUGS OR DIET
Yagudina R, Kulikov AU, Arinina EE Moscow Medical Academy, Moscow, Russia OBJECTIVES: To analyze the effectiveness and safety of three treatment regimens, and to project and compare long-term outcomes and costs of complications of type 2 diabetes mellitus (T2DM). METHODS: Data of 3678 patients (mean age 49.6 ± 0.19 years; 47% men; mean diabetes's duration-6 years) included in "evaluation of diabetes mellitus complications" program were taken for mathematic simulation using the validated Center for Outcomes Research (CORE) Diabetes Model. Patients were randomly divided into three groups: insulin therapy (NovoMix® 30), oral antidiabetic drugs (OAD; combination of glibenclamide + metformin in most cases) and diet. Life expectancy, cumulative incidence of cardiovascular, ocular events and health care costs were estimated over period duration-50 years. RESULTS: Estimated life expectancy was higher in insulin group compared with OAD and diet groups (17.2, 16.5, and 16 .0 years). The best QALY's results were also achieved in insulin group (10.7, 10.2 and 9.9 years) due to decreased rates of myocardial infarction (morbidity/mortality), decompensated heart failure, ocular complications and diabetic retinopathy. Higher direct costs for years of life gained in insulin group (1287, 1203, and 1180 thousands of rub.) were associated with concomitant decreasing of indirect costs (362.7, 382.5, and 381.3 thousands of rub.). The costs for one patient with T2DM per 1 year were nearly the same in three groups (95.9, 95.9, and 97.6 thousands of rub.). CONCLUSIONS: use of the CORE Diabetes Model life expectancy, diabetes complications, and costs favored insulin NovoMix® 30 therapies compared with OAD or diet in treatment of T2DM.
